RxDoctor Payments Data

Michael Wallace, MD

Ophthalmology · Mobile, ALNPI 1376922948

Payments from drug & device makers

What this record shows

This record is dominated by other: $5,027 of the $6,794 with a category attached, or 74.0%. Carl Zeiss Meditec Digital Innovations LLC accounts for 74.0% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2024 at $5,399 and has fallen 90.2% since, to $530 in 2025.

$6,794in general payments, 2019–2025

Across 69 payments — averaging $98.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec Digital Innovations LLC$5K
  • AbbVie$312
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$147
  • Bausch & Lomb Americas Inc.$138
  • Johnson & Johnson Surgical Vision, Inc.$138
  • Glaukos Corporation$135
  • plus $897 from 16 others

What the payments were for

  • Food & beverage$1,76726%
  • Other$5,02774%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,794 in reported general payments places this provider in the 85th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$140,680
Medicare patients
324
Services billed
1,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine74$54,098
RhopressaNetarsudil Mesylate143$48,614
Restasis MultidoseCyclosporine44$28,663
Cyclosporine62$22,881
VyzultaLatanoprostene Bunod34$17,830
Travoprost137$15,881
LumiganBimatoprost41$11,137
XiidraLifitegrast16$10,949
RocklatanNetarsudil Mesylat/Latanoprost28$9,259
Latanoprost770$9,190
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol36$7,467
CombiganBrimonidine Tartrate/Timolol25$5,400
SimbrinzaBrinzolamide/Brimonidine Tart21$5,369
Brinzolamide27$5,341
Dorzolamide Hcl196$4,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose, Lumigan, Combigan, Alphagan P$312$102,068199 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$138$28,77950 claims
AlconSimbrinza$133$5,36921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →